These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36541643)

  • 21. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
    Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
    J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study.
    Buchacz K; Wiegand R; Armon C; Chmiel JS; Wood K; Brooks JT; Palella FJ
    HIV Clin Trials; 2015 Aug; 16(4):139-46. PubMed ID: 26126549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
    Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial.
    Torres B; Guardo AC; Squarcia M; Diaz A; Fabra A; Caballero M; Ugarte A; Leal L; Gatell JM; Plana M; Garcia F
    HIV Med; 2021 Sep; 22(8):674-681. PubMed ID: 34288357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials.
    Shu Y; Deng Z; Wang H; Chen Y; Yuan L; Deng Y; Tu X; Zhao X; Shi Z; Huang M; Qiu C
    AIDS Res Ther; 2021 May; 18(1):25. PubMed ID: 33933131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.
    El Kamari V; Moser C; Hileman CO; Currier JS; Brown TT; Johnston L; Hunt PW; McComsey GA
    Clin Infect Dis; 2019 Apr; 68(8):1394-1401. PubMed ID: 30137242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switch to efavirenz (EFV) after protease-inhibitor (PI)-failure: explorative analysis of outcome by baseline viral VS tolerability failure.
    Khaykin P; Postel N; Reeb I; Staszewski S
    Eur J Med Res; 2008 Apr; 13(4):169-72. PubMed ID: 18504172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.
    Karris MY; Jain S; Day TR; Pérez-Santiago J; Goicoechea M; Dubé MP; Sun X; Spina C; Daar ES; Haubrich RH; Morris S;
    HIV Clin Trials; 2017 Mar; 18(2):67-74. PubMed ID: 28134057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4).
    Potard V; Simon A; Lacombe JM; Parienti JJ; Costagliola D;
    Clin Infect Dis; 2016 Nov; 63(9):1254-1261. PubMed ID: 27543648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients.
    Krikke M; Tesselaar K; van den Berk GEL; Otto SA; Freriks LH; van Lelyveld SFL; Visseren FJL; Hoepelman AIM; Arends JE
    HIV Clin Trials; 2018 Apr; 19(2):75-83. PubMed ID: 29770748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy.
    Annavajhala MK; Khan SD; Sullivan SB; Shah J; Pass L; Kister K; Kunen H; Chiang V; Monnot GC; Ricupero CL; Mazur RA; Gordon P; de Jong A; Wadhwa S; Yin MT; Demmer RT; Uhlemann AC
    mSphere; 2020 Feb; 5(1):. PubMed ID: 32024712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
    Lucas GM; Chaisson RE; Moore RD
    AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
    De Castro N; Marcy O; Chazallon C; Messou E; Eholié S; N'takpe JB; Bhatt N; Khosa C; Timana Massango I; Laureillard D; Chau GD; Domergue A; Veloso V; Escada R; Wagner Cardoso S; Delaugerre C; Anglaret X; Molina JM; Grinsztejn B;
    Lancet Infect Dis; 2021 Jun; 21(6):813-822. PubMed ID: 33667406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
    Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
    J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.
    Curran A; Martinez E; Saumoy M; del Rio L; Crespo M; Larrousse M; Podzamczer D; Burgos J; Lonca M; Domingo P; Gatell JM; Ribera E
    AIDS; 2012 Feb; 26(4):475-81. PubMed ID: 22112606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV.
    Negredo E; Jiménez M; Puig J; Loste C; Pérez-Álvarez N; Urrea V; Echeverría P; Bonjoch A; Clotet B; Blanco J
    PLoS One; 2020; 15(9):e0238575. PubMed ID: 32941476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort.
    Naumann U; Moll A; Schleehauf D; Lutz T; Schmidt W; Jaeger H; Funke B; Witte V
    Int J STD AIDS; 2017 Aug; 28(9):893-901. PubMed ID: 28385065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Starting or Switching to an Integrase Inhibitor-Based Regimen Affects PTSD Symptoms in Women with HIV.
    Kamkwalala AR; Wang K; O'Halloran J; Williams DW; Dastgheyb R; Fitzgerald KC; Spence AB; Maki PM; Gustafson DR; Milam J; Sharma A; Weber KM; Adimora AA; Ofotokun I; Sheth AN; Lahiri CD; Fischl MA; Konkle-Parker D; Xu Y; Rubin LH
    AIDS Behav; 2021 Jan; 25(1):225-236. PubMed ID: 32638219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.